ANG LIFESCIENCES INDIA LTD.

NSE : NABSE : 540694ISIN CODE : INE236W01016Industry : Pharmaceuticals & DrugsHouse : Private
BSE45.08-1.75 (-3.74 %)
PREV CLOSE ( ) 46.83
OPEN PRICE ( ) 48.99
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 92879
TODAY'S LOW / HIGH ( )44.49 49.17
52 WK LOW / HIGH ( ) 44.4992.19
NSE
This Company is not listed in NSE
( in Million)
Select year
ParticularsMar2023Mar2022
Profit Before Tax26.25535.01
Adjustment206.97167.96
Changes In working Capital65.15-450.53
Cash Flow after changes in Working Capital298.37252.44
Cash Flow from Operating Activities263.77247.17
Cash Flow from Investing Activities-93.25-444.10
Cash Flow from Financing Activities-170.74199.28
Net Cash Inflow / Outflow-0.222.35
Opening Cash & Cash Equivalents3.461.11
Cash & Cash Equivalent on Amalgamation / Take over / MergerNANA
Cash & Cash Equivalent of Subsidiaries under liquidationsNANA
Translation adjustment on reserves / op cash balalces frgn subsidiariesNANA
Effect of Foreign Exchange FluctuationsNANA
Closing Cash & Cash Equivalent3.243.46

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.